China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has launched its Integrated Biologics CRDMO Center in the Fengxian district of Shanghai. The new facility will enhance the company’s development and manufacturing capacity, offering end-to-end services for diversified biologics to accelerate project timelines for global clients. This marks WuXi Biologics’ ninth operational site in China.
Center Overview
The 1.6 million-square-foot Integrated Biologics CRDMO Center began construction in November 2018. The initial phase, operational since 2020, provides a comprehensive range of biologics research services, including target evaluation, reagent generation, antibody generation, lead optimization, complex biologics discovery, and Pre-Clinical Candidates (PCC) identification, as well as Investigational New Drug (IND) candidate selection. The center also features proprietary technology platforms WuXiBody and SDarBody for bispecific and multi-specific antibody discovery.
Facility Details
The opening includes the drug substance facility (MFG17) and two drug product facilities (DP14 and DP15), designed for maximum flexibility to meet the demand for clinical drug substance and drug product manufacturing of innovative biologics at various scales and volumes. These facilities will further enhance WuXi Biologics’ clinical manufacturing network and ensure a robust node of global capacity following their GMP release in 2023.
Future Implications
The launch of the Integrated Biologics CRDMO Center underscores WuXi Biologics’ commitment to expanding its global footprint and enhancing its service offerings. This new facility will enable the company to better support its global clients, accelerating the development and manufacturing of innovative biologics and contributing to the advancement of healthcare solutions worldwide.-Fineline Info & Tech
